Upsher-Smith Labs., Inc. v. La. Wholesale Drug Co.
570 U.S. 913, 133 S. Ct. 2849, 186 L. Ed. 2d 904, 81 U.S.L.W. 3697, 2013 WL 3155223, 2013 U.S. LEXIS 4861
Supreme Court of the United States·Decided June 24, 2013·No. No. 12–265.·Published·Cited by 13 cases
Opinion
Free access — add to your briefcase to read the full text and ask questions with AI
Upsher-Smith Labs., Inc. v. La. Wholesale Drug Co., 570 U.S. 913, 133 S. Ct. 2849, 186 L. Ed. 2d 904, 81 U.S.L.W. 3697, 2013 WL 3155223, 2013 U.S. LEXIS 4861 (2013).
570 U.S. 913 (Upsher-Smith Labs., Inc. v. La. Wholesale Drug Co.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Related
FWK Holdings LLC v. Shire PLC (Direct Purchaser Antitrust Class Action Complaint)
D. Massachusetts, 2019
Apotex, Inc. v. Cephalon, Inc.
321 F.R.D. 220 (E.D. Pennsylvania, 2017)
In Re Class 8 Transmission Indirect Purchaser Antitrust Litigation
679 F. App'x 135 (Third Circuit, 2017)
In Re: Loestrin 24 FE v.
First Circuit, 2016
American Sales Co. v. Warner Chilcott Co.
814 F.3d 538 (First Circuit, 2016)
King Drug Co. of Florence, Inc. v. Cephalon, Inc.
309 F.R.D. 195 (E.D. Pennsylvania, 2015)
King Drug Co of Florence Inc v. Smithkline Beecham Corporation
791 F.3d 388 (Third Circuit, 2015)
United Food & Commercial Workers Local 1776 v. Teikoku Pharma USA, Inc.
74 F. Supp. 3d 1052 (N.D. California, 2014)
In re Lipitor Antitrust Litigation
46 F. Supp. 3d 523 (D. New Jersey, 2014)
In re Nexium (Esomeprazole) Antitrust Litigation
297 F.R.D. 168 (D. Massachusetts, 2013)
In re Nexium
968 F. Supp. 2d 367 (D. Massachusetts, 2013)